Legend Biotech (LEGN) analyst forecast and price target
Analyst forecast
Consensus of 17 analyst ratings
Based on 8 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $68.00 from $74.00 | Oct 13, 2026 |
| JP Morgan | Maintained | Neutral | $33.00 from $35.00 | Oct 9, 2026 |
| RBC Capital | Maintained | Outperform | $56.00 from $58.00 | Oct 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $65.00 | Sep 30, 2026 |
| Barclays | Maintained | Overweight | $74.00 from $78.00 | Sep 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $65.00 | Sep 4, 2026 |
| Barclays | Maintained | Overweight | $78.00 from $80.00 | Aug 12, 2026 |
| RBC Capital | Maintained | Outperform | $58.00 from $59.00 | Aug 12, 2026 |
| Oppenheimer | Downgraded | Outperform → Perform | $40.00 from $75.00 | Aug 12, 2026 |
| Morgan Stanley | Maintained | Overweight | $49.00 from $48.00 | Aug 12, 2026 |
| TD Cowen | Maintained | Hold | $24.00 from $29.00 | Aug 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $65.00 | Jul 28, 2026 |
| RBC Capital | Maintained | Outperform | $59.00 from $63.00 | Jul 27, 2026 |
| UBS | Downgraded | Buy → Neutral | $28.00 from $49.00 | Jul 24, 2026 |
| JP Morgan | Maintained | Neutral | $35.00 | Jul 13, 2026 |
| RBC Capital | Maintained | Outperform | $63.00 from $64.00 | Jul 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $65.00 from $50.00 | Jun 3, 2026 |
| UBS | Maintained | Buy | $49.00 from $31.00 | Jun 3, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $50.00 | May 18, 2026 |
| RBC Capital | Maintained | Outperform | $64.00 from $62.00 | May 13, 2026 |
Frequently asked questions
What is the price target for LEGN stock?
The average 12-month analyst price target for Legend Biotech (LEGN) is $45.38, with a high estimate of $68.00 and a low of $24.00, across 8 analysts.
Is LEGN a buy, sell, or hold?
Analysts covering Legend Biotech currently average a Buy rating: 12 buy, 5 hold and 0 sell, from 17 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for LEGN?
The average price target of $45.38 implies 129.17% upside from the last price of $19.80.
What is the latest analyst rating on LEGN?
On Oct 13, 2026, Barclays maintained Legend Biotech at Overweight with a price target of $68.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.